Answers are grounded in this paper and cite their sources.
Translational framework uncovers tumor microenvironment gatekeeping in obesity-conditioned triple-negative breast cancer, suggesting metrics to improve drug development fidelity.
Preclinical cancer models do not always recapitulate clinical treatment response, as therapeutic response may depend on tissue context the model does not reproduce. Using obesity-conditioned triple-negative breast cancer as a lens, we argue that the tumor microenvironment acts through dual gates—controlling access and altering behavior—and propose the recapitulation gap as a measurable model-to-patient divergence to guide fit-for-purpose drug development.
No takes yet. Share an insight, caveat, or question.
Budhwani et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: